Published Online
on February 3, 2003

A more recent version of this article appeared on February 11, 2003

This Article Full Text (PDF) All Versions of this Article: 107/5/679    most recent 01.CIR.0000055739.13639.D7v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Isoda, K. Articles by Ohsuzu, F. Search for Related Content PubMed PubMed Citation Articles by Isoda, K. Articles by Ohsuzu, F. Related Collections Ion channels/membrane transport

Submitted on November 7, 2002
Revised on December 18, 2002
Accepted on December 19, 2002

Osteopontin Transgenic Mice Fed a High-Cholesterol Diet Develop Early Fatty-Streak Lesions

Kikuo Isoda MD, PhD^*, Yashuhiro Kamezawa MD, Makoto Ayaori MD, Masatoshi Kusuhara MD, PhD, Norihiro Tada PhD, and Fumitaka Ohsuzu MD, PhD

From Internal Medicine I, National Defense Medical College (K.I., Y.K., M.A., M.K., F.O.), Tokorozawa, Japan, and the Division of Biomedical Research Resources, Juntendo University School of Medicine (N.T.), Tokyo, Japan.

^* To whom correspondence should be addressed. E-mail: isoda{at}me.ndmc.ac.jp.

Background--Osteopontin (OPN) is a noncollagenous adhesion protein found at the site of atherosclerotic lesions. However, it has not yet been clarified whether or not OPN can promote atherosclerotic lesions.

Methods and Results--We investigated the contribution of OPN to atherosclerosis by evaluating aortic sinus lesions of both OPN transgenic (Tg) and non-Tg mice fed an atherogenic diet (1.25% cholesterol) for 16 weeks. The atherosclerotic lesions were found to be significantly larger in OPN-Tg compared with those in non-Tg (17 859±2010 versus 6469±485 µm², P<0.01). The lesions in both mice were fatty-streak lesions with an accumulation of mononuclear cells and lipids. We next investigated the production of interleukin (IL)-10 by macrophages from both mice. Compared with the non-Tg mice, a 42% (P<0.01) and 73% (P<0.001) decrease in the IL-10 production was identified in the OPN-Tg mice either without or with lipopolysaccharide.

Conclusions--The expression of OPN induces fatty-streak lesion formation in mice fed an atherogenic diet and inhibits IL-10 production by macrophages, thus suggesting that OPN plays an important role in the development of fatty-streak lesions in vivo.

Key words: atherosclerosis • genes • interleukins

This article has been cited by other articles:

				M. Koshikawa, K. Aizawa, H. Kasai, A. Izawa, T. Tomita, S. Kumazaki, H. Tsutsui, J. Koyama, S. Shimodaira, M. Takahashi, et al. Elevated Osteopontin Levels in Patients With Peripheral Arterial Disease Angiology, February 1, 2009; 60(1): 42 - 45. [Abstract] [PDF]

				F. W. Kiefer, M. Zeyda, J. Todoric, J. Huber, R. Geyeregger, T. Weichhart, O. Aszmann, B. Ludvik, G. R. Silberhumer, G. Prager, et al. Osteopontin Expression in Human and Murine Obesity: Extensive Local Up-Regulation in Adipose Tissue but Minimal Systemic Alterations Endocrinology, March 1, 2008; 149(3): 1350 - 1357. [Abstract] [Full Text] [PDF]

				S. H. Mangan, A. V. Campenhout, C. Rush, and J. Golledge Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-{alpha} associated with induction of angiopoietin-2 Cardiovasc Res, December 1, 2007; 76(3): 494 - 505. [Abstract] [Full Text] [PDF]

				M. Scatena, L. Liaw, and C. M. Giachelli Osteopontin: A Multifunctional Molecule Regulating Chronic Inflammation and Vascular Disease Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2302 - 2309. [Abstract] [Full Text] [PDF]

				J. Gomez-Ambrosi, V. Catalan, B. Ramirez, A. Rodriguez, I. Colina, C. Silva, F. Rotellar, C. Mugueta, M. J. Gil, J. A. Cienfuegos, et al. Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3719 - 3727. [Abstract] [Full Text] [PDF]

				N. Tanaka, Y. Momiyama, R. Ohmori, A. Yonemura, M. Ayaori, M. Ogura, S. Sawada, M. Kusuhara, H. Nakamura, and F. Ohsuzu Effect of atorvastatin on plasma osteopontin levels in patients with hypercholesterolemia. Arterioscler Thromb Vasc Biol, August 1, 2006; 26(8): e129 - e130. [Full Text] [PDF]

				P. Minoretti, C. Falcone, M. Calcagnino, E. Emanuele, M. P. Buzzi, E. Coen, and D. Geroldi Prognostic significance of plasma osteopontin levels in patients with chronic stable angina Eur. Heart J., April 1, 2006; 27(7): 802 - 807. [Abstract] [Full Text] [PDF]

				R. Karra, S. Vemullapalli, C. Dong, E. E. Herderick, X. Song, K. Slosek, J. R. Nevins, M. West, P. J. Goldschmidt-Clermont, and D. Seo Molecular evidence for arterial repair in atherosclerosis PNAS, November 15, 2005; 102(46): 16789 - 16794. [Abstract] [Full Text] [PDF]

				T. Matsuki, K. Isoda, R. Horai, A. Nakajima, Y. Aizawa, K. Suzuki, F. Ohsuzu, and Y. Iwakura Involvement of Tumor Necrosis Factor-{alpha} in the Development of T Cell-Dependent Aortitis in Interleukin-1 Receptor Antagonist-Deficient Mice Circulation, August 30, 2005; 112(9): 1323 - 1331. [Abstract] [Full Text] [PDF]

				K. Isoda, S. Sawada, N. Ishigami, T. Matsuki, K. Miyazaki, M. Kusuhara, Y. Iwakura, and F. Ohsuzu Lack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E-Deficient Mice Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1068 - 1073. [Abstract] [Full Text] [PDF]